期刊
NATURE MEDICINE
卷 19, 期 8, 页码 998-1004出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3267
关键词
-
资金
- US National Institutes of Health [HL093172, HL099117, EB009689]
- Burroughs Wellcome Fund Career Award in the Biomedical Sciences, American Heart Association [EIA14420025]
- California Institute of Regenerative Medicine (CIRM) [DR2-05394, TR3-05556]
- CIRM Tools Technology II
- Bio-X graduate student fellowship
- Howard Hughes Medical Institute research training fellowships
Human pluripotent stem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlimited self renewal and pluripotent differentiation. These advances have recently culminated in the first-in-human PSC clinical trials by Geron, Advanced Cell Technology and the Kobe Center for Developmental Biology for the treatment of spinal cord injury and macular degeneration. Despite their therapeutic promise, a crucial hurdle for the clinical implementation of human PSCs is their potential to form tumors in vivo. In this Perspective, we present an overview of the mechanisms underlying the tumorigenic risk of human PSC-based therapies and discuss current advances in addressing these challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据